Flash Finance

Sunrest Lifescience LimitedSUNRESTCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Mar 2026 3 quarters of data
Consolidated Standalone
₹33.70
MCap ₹17 Cr
Sunrest Lifescience Limited — Stock analysis & AI research Sunrest Lifescience Limited — Seasonality — best & worst months Sunrest Lifescience Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹37 Cr
Sales · Mar 2026
₹7 Cr
Operating Profit · Mar 2026
18.3%
OPM % · Mar 2026
₹7 Cr
Net Profit · Mar 2026
₹3.94
EPS · Mar 2026

📝 Sunrest Lifescience Limited — results explained

Quarter ended March 2026 (Q4 FY26)

Sunrest Lifescience Limited reported revenue of ₹37 crore for the quarter ended March 2026 (Q4 FY26).

Net profit stood at ₹7 crore. Earnings per share (EPS) came in at ₹3.94.

Operating profit stood at ₹7 crore — an operating margin (OPM) of 18.3%.

Valuation snapshot

At the current price of ₹33.70, SUNREST has a market capitalisation of ₹17 crore.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Mar 2026, promoters held 53.50%, public shareholders 46.50% of Sunrest Lifescience Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹17 Cr
Current Price ?
₹33.7
P/E ?
N/A
Industry P/E ?
37.20
P/B ?
0.85
P/S ?
N/A
P/FCF ?
-6.30
Enterprise Value ?
₹35 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
28.6%
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹37 Cr
PAT — latest qtr ?
₹7 Cr
YoY qtr sales growth ?
N/A
YoY qtr profit growth ?
N/A
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹17 Cr
Debt to Equity ?
0.85
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
53.50%
Change in promoter holding ?
-16.41%
Pledged percentage ?
N/A
Market
Return 3 months ?
-3.7%
Return 6 months ?
-11.3%

🗓️ Quarterly results (3 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best
Metric Sep 2024Sep 2025Mar 2026 YoY % QoQ %
Sales 153437 — —
Operating Profit 127 — —
Other Income 003 — —
Interest 011 — —
Depreciation 011 — —
Profit Before Tax 118 — —
Net Profit 117 — —
EPS 0.670.403.94 — —
OPM % 5.9% 7.2% 18.3% — —

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 2 periods)

Metric Mar 2025Mar 2026 % Chg
Equity Capital 4.294.29 +0.0%
Reserves 12.0216.14 +34.3%
Borrowings 12.0517.46 +44.9%
Other Liabilities 30.2933.52 +10.7%
Total Liabilities 58.6571.41 +21.8%
Fixed Assets 4.368.55 +96.1%
CWIP 0.000.00 —
Investments 0.000.00 —
Other Assets 54.2962.86 +15.8%
Total Assets 58.6571.41 +21.8%

💧 Cash Flow (latest 2 periods)

Metric Mar 2025Mar 2026 % Chg
Cash from Operating Activity 2.92-0.05 -101.7%
Cash from Investing Activity -1.15-2.91 -153.0%
Cash from Financing Activity -0.333.99 +1309.1%
Net Cash Flow 1.451.03 -29.0%
Free Cash Flow 1.76-2.76 -256.8%
CFO/OP 112%14% -87.5%

➗ Ratios (latest 2 periods)

Metric Mar 2025Mar 2026 % Chg
Debtor Days 397.34167.27 -57.9%
Inventory Days 174.78140.69 -19.5%
Days Payable 416.60173.35 -58.4%
Cash Conversion Cycle 155.52134.62 -13.4%
Working Capital Days 228.33155.88 -31.7%
ROCE % —28.55% —

👥 Shareholding (latest 4 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026 % Chg
Promoters 69.91%54.00%53.50%53.50% +0.0%
Public 30.09%47.00%46.50%46.50% +0.0%
No. of Shareholders 455498491492 +0.2%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 SUNREST Sunrest Lifescience ₹61.65 32 — — — — — — — — —
❓ Frequently asked questions
What was Sunrest Lifescience Limited's revenue in Q4 FY26?
Sunrest Lifescience Limited reported revenue of ₹37 crore for the quarter ended March 2026 (Q4 FY26).
What was Sunrest Lifescience Limited's net profit in Q4 FY26?
Net profit stood at ₹7 crore. Earnings per share (EPS) came in at ₹3.94.
What is SUNREST's market capitalisation and P/E ratio?
At the current price of ₹33.70, SUNREST has a market capitalisation of ₹17 crore.
Who owns Sunrest Lifescience Limited? (shareholding pattern)
As of Mar 2026, promoters held 53.50%, public shareholders 46.50% of Sunrest Lifescience Limited.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI